- Home
- FSP vs IPHA Comparison
FSP vs IPHA Comparison
Compare FSP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | IPHA |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.3M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FSP | IPHA |
|---|---|---|
| Price | $0.98 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 684.6K | 22.5K |
| Earning Date | 10-28-2025 | 09-17-2025 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | $14,839,695.00 |
| Revenue This Year | $4.36 | $22.29 |
| Revenue Next Year | $0.81 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.47 |
| 52 Week High | $2.21 | $3.51 |
Technical Indicators
Market Signals| Indicator | FSP | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 42.81 |
| Support Level | $0.90 | $1.85 |
| Resistance Level | $0.99 | $1.91 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 47.04 | 11.63 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.